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a b s t r a c t
In a study conducted in a non-endemic area, a live attenuated Japanese encephalitis chimeric virus vac-
cine (JE-CV) was found to provide 97% seroprotection at 6 months in JE-naive adults after 1 dose, and 87%
of those protected at 6 months were still protected at 5 years. Because long-term seroprotection data
are essential for decision-making on the need and timing of boosters, we applied statistical models to
this dataset to predict individuals’ neutralizing antibody titres and seroprotection up to 25 years post-
vaccination. Three types of statistical model (linear, piecewise linear and exponential-type) with ﬁxed
and random effects were constructed to model antibody decline from the observed peak in antibody lev-
els measured 28 days after vaccination. Individual seroprotection was based on the accepted threshold
of 1:10 dilution units (antibody titre ≥10). The piecewise linear mixed model provided best ﬁt amongsturation of protection all tested models and identiﬁed 2 periods of antibody decline: an initial period of rapid decline followed
by a period of much slower decline (50 times) starting on average 3.2 months (5th to 95th percentile
range: 1.4–7.3) after vaccination. Predicted median antibody titres at 10 years were 38 (<10–174) and
the corresponding seroprotection rate was 85.5% (72.7–94.9). The estimated median duration of sero-
protection was 21.4 years (5th to 95th percentile range: 7.3–34.0). This analysis suggests that one dose of
JE-CV confers to most adults a high level of protection against Japanese encephalitis for at least 10 years.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.           
. Introduction
Japanese encephalitis (JE) virus is the most common cause of
accine preventable encephalitis, occurring throughout most of
sia and the western Paciﬁc [1,2]. Transmitted by mosquitoes
nd sustained in the environment by pigs and water-fowl, JE is
esponsible for an estimated 35,000–50,000 annual cases with
pproximately 20–30% case-fatality. Among survivors, 30–50%will
ave neurological or psychiatric sequelae [1,3]. In endemic coun-
ries JE is primarily a rural disease of children, but in new outbreak
egions, urban settings and in travellers, JE can occur in persons
f any age [2,4]. Over the past decade, there has been a pattern of
eographical expansion of JE and recurrent outbreaks in Vietnam,
epal, and India [5].
In countrieswherehighvaccinationcoveragehasbeenachieved,
uch as Japan, South Korea, Taiwan and Thailand, JE has become
rare disease [5]. The reduced risk of disease has contributed to
ecreasing the acceptability of mouse-brain derived vaccines, trig-
ering the development of new vaccines that are less reactogenic
∗ Corresponding author at: Sanoﬁ Pasteur, 2 Avenue Pont Pasteur, 69007 Lyon
edex 07, France. Tel.: +33 4377804; fax: +33 437377202.
E-mail address: laurent.coudeville@sanoﬁpasteur.com (L. Coudeville).
264-410X/© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
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and have simpler immunization schedules [6]. However, many
countries where JEV is endemic currently consider that they have
insufﬁcient information to enable effective decision-making on JE
immunization programs, particularly as newer 1 and 2-dose JE vac-
cines replace the diminishing stockpiles of the 3-dose mouse-brain
derived JE vaccine. Part of this uncertainty stems from insufﬁcient
knowledge on the characteristics of the newer vaccines includ-
ing long-term seroprotection which is essential to assess need and
timing of boosters.
One such new vaccine is a Japanese encephalitis chimeric virus
vaccine (JE-CV; ImojevTM; sanoﬁ-pasteur), a live, attenuated prod-
uct grown in Vero cells. The vaccine virus was constructed by
removing pre-membrane and envelope coding sequences fromyel-
low fever vaccine virus (strain 17D) and replacing them with the
corresponding sequences from the attenuated JE viral strain SA14-
14-2 [7,8].
To better inform decision-making on JE immunization, we used
5 year follow-up data on neutralizing antibody titres from a cohort
of adults who received a single dose JE-CV. These data provide in
the case of Japanese encephalitis a convenient way to assess the
duration of protection conferred by vaccination since the relation-
ship between antibody levels and protection is well established: a
1:10 antibody titre is accepted by regulatory authorities [2,9] as a
surrogate marker of protection for the licensure of new JE vaccines.
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 recent publication also conﬁrmed the relevance of this threshold
10].
We used here these antibody persistence data to construct sta-
istical models for predicting the evolution of antibody titres up to
5 years after vaccination as well as the corresponding proportion
f seroprotected individuals and the median duration of protection
ith a single dose of JE-CV vaccine.
. Methods
.1. Study data
Data  for our analysis are from a randomized controlled trial,
escribed elsewhere [11], to assess safety and immunogenicity of
 or 2 doses of JE-CV in healthy adult volunteers recruited at a sin-
le study centre in Australia. The vaccine used in this study was
roduced at pilot scale as a liquid formulation [12]. 202 individuals
ere screened and randomized in a 1:1 ratio to receive either JE-CV
n day 0 or on day 28. At month 6, a sample of 98 participants from
ach group available and willing to participate received a second
noculation of JE-CV, while 103 did not. Those who  received either
 single dose or two doses were subsequently invited to participate
n a long term follow-up study to 60 months post initial vaccina-
ion with annual immunogenicity assessments commencing at 12
onths. Immunogenicity data were therefore available at days 0,
4, 28 and 56, month 6 and years 1–5. Immunogenicity assessments
ere based on neutralizing antibodies to JE-CV virus by plaque
eduction neutralization test with a 50% endpoint (PRNT50) and are
xpressed as the reciprocal dilution factor (1/dil). For our analysis,
e only used data from the 99 subjects who received a single-dose
f JE-CV and for whom data were available at 28 days or later; 46
ere still available for immunogenicity assessments by year 5.
Fig. 1 shows the observed antibody titres between day 0 and
ear 5 in subjects receiving a single dose of JE-CV and the propor-
ion of subjects who are seroprotected, having antibody titres ≥10.
itres were found to rise rapidly, reaching a median value of 230 by
ay 28 (5th to 95th percentile range: 35.7–2140), at which point
7.9% (95% conﬁdence interval (CI): 92.8–99.7) of subjects were
eroprotected. By month 6, median titres had declined to 149 (5th
o 95th percentile range: 19–1270), and 96.8% (95% CI: 90.9–99.3)
ere seroprotected. Titres continued to decline until year 5, when
he median titre was 70.0 (5th to 95th percentile range: <10–304)
nd the seroprotection rate was 93.3% (95% CI: 82.1–98.6%).
.2.  Statistical models
Statistical  models were constructed to estimate the evolution
f antibody titres over time and to predict, at the individual level,
ow long antibody titres will remain above the protective thresh-
ld. The raw data summarized above revealed three distinct periods
f evolution of antibody titres: a rapid rise from day 0 to 28, rapid
ecay from day 28 to month 6 and slow decay from month 6.
ince the focus here is on long-term persistence rather that anti-
ody rise induced by vaccination, we analyzed data from day 28
hen observed titres were highest and developed models focused
n antibody decay from that point in time.
Given the highly nonlinear nature of antibody decay, and the
mportance of individual variations in vaccine-induced antibody
esponses, we constructed three alternative mixed-effects models.
The ﬁrst model estimated linear antibody decay and contained
xed and random effects for both slope and intercept parameters:
ij = (a + ai) + (b + bi) · tj + εij (2012) 2510– 2515 2511
where Yij is the log of the neutralizing antibody titre for subject i
observed at time tj, a and ai are the population-level (ﬁxed effect)
and individual-level (random effect) intercepts and b and bi are
the population-level and individual-level slope corresponding to
the rate of linear antibody decay. εij is the residual error between
model prediction and the observed value.
The second model was  an exponential-type model constructed
from day 28 data with ﬁxed and random effects for slope (a, ai),
intercept (b, bi) and exponent (c, ci) parameters:
Yij = (a + ai) + (b + bi) · tc+cjj + εij
The third model was  a 2-period piecewise linear model with
ﬁxed and random effects for the intercept (a, ai), 2 slope parameters
(b, bi, b2, b2i) and a change point Si, representing the point in time
when the change in the rate of antibody decay occurs.
Yij = (a + ai) + (b + bi) · tj + εij, for t = Si
Yij = (a + ai) + (b + bi) · Si + (b2 + b2i) · (tj − Si) + εij, for t > Si
All models were constructed using a Bayesian Monte-Carlo
Markov chain approach [13] and were implemented with Open-
Bugs V3.12.1. Posterior summary statistics were based on 3 Markov
chains of 40,000 lengths after a burn-in period of 60,000 iter-
ations. Convergence of the model estimates was assessed using
Gelman–Rubin statistics [14] as well as inspection of the param-
eters’ iteration history and posterior densities. Comparison of
competing models was  based on the Deviance Information Crite-
rion (DIC) [15], the analysis of residuals at discrete times (t = 1, 3,
5 years) and scatterplots of predicted versus observed values. The
DIC is a generalization of the Akaike Information Criterion and is
suitable for assessing mixed-effects models like ours. There is no
established test for assessing differences in DIC. The model with the
lowest DIC can be considered to be the most predictive, in a simi-
lar manner to Akaike’s criterion. In accordance with Spiegelhalter
et al. [15] we considered that a difference of at least 3 is indicative
of a difference in the quality of the adjustment obtained for two
different models. In addition, the comparison between predicted
and observed indicates the average direction and bias in estimates
of individual antibody titres.
2.3. Model inference
Fitted  models were used to predict individual antibody titres up
to 25 years after vaccination. We also used the accepted threshold
titre of 1:10 [2,9] for determining at different time points the pro-
portion of subjects still protected against JE. Finally, we calculated
each individual’s duration of protection on the basis of this thresh-
old. Given the model’s individual and population-level parameter
estimates, we set Yij = log(10) and solved for t, which represents the
point in time when the subject’s titre wanes to below 10. This gave
a distribution of duration of protection for our 99 subjects.
3.  Results
3.1. Model ﬁtting
Table  1 gives the parameter estimates and ﬁt statistics for the
three models. The DIC was smaller for the piecewise linear model
indicating it best ﬁt the observed data. Figs. 2 and 3 illustrate the
ability of this model to reproduce the observed titres and sero-
protection rates. The scatterplot in Fig. 4 conﬁrms the ability of the
piecewise linear model to provide a good ﬁt to most of the observed
data with the possible exception of outlying antibody titres (>1000
or <10).
2512 K.  Desai et al. / Vaccine 30 (2012) 2510– 2515
Fig. 1. (a) Boxplot of the observed Ab titres between time 0 and 5 years in subjects receiving a single dose of JE-CV. The green line represents the accepted threshold of
protection of 1:10/dilutions. (b) The proportion of subjects who are seroprotected, i.e. having Ab titre ≥1:10 dilution. Figures indicated in yellow are the number of subjects
for  which immunological assessments were available at each time point. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version  of the article.)
Table  1
Parameter estimates and ﬁt statistics for mixed models of JE antibody persistence.
Model Mean parameter estimates over 99 subjects and 5th to 95th percentile range DIC
Linear Intercept (a + ai) 5.13 (5.01, 5.24) 1484
Slope (b + bi) −0.215 (−0.266, −0.164)
Exponential-type Intercept (a + ai) 13.6 (7.06, 28.71) 1412
Slope (b + bi) −8.895 (−24.02, −2.328)
Exponent (c + ci) 0.046 (0.012, 0.128)
Piecewise linear Intercept  (a + ai) 5.81 (5.36, 6.58) 1345
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On the basis of these results, we chose the piecewise linear
odel. For this model, the ﬁrst period slope parameter suggests
n average annual rate of titre decay of 5.81 (log units). This rate
f decay continues for only 0.267 years or 3.2 months. After this
nitial period of rapid decline, the second period slope parameter
ndicates a 50-fold slower rate of decay of 0.109 (log units)..2.  Predicted antibody titres
Fig. 2 illustrates the population and individual-level (N = 99) pre-
ictions of titre from day 28 to year 10, based on the piecewise
ig. 2. Spaghetti plot of the population (black line) and individual ﬁts (blue lines) of
9 subjects’ Ab titre values from day 28 to 10 years estimated using the piecewise
inear  model. The population average can be seen to closely match the observed
edian  Ab titres (circles) to year 5. The horizontal green line represents the accepted
hreshold of protection corresponding to 1:10 dilutions. The red segment indicates
he  observation period for our data and the blue segment the period of time over
hich  the model is extrapolated. (For interpretation of the references to colour in
his ﬁgure legend, the reader is referred to the web  version of the article.)−5.41 (−14.0, −1.48)
−0.109 (−0.172, −0.034)
0.267 (0.113, 0.61)
linear model. The population average can be seen to closely match
the observed median titres to year 5. We  did not detect in Fig. 2a
bias in the ability of the model to ﬁt observed antibody titres for
speciﬁc timepoints.
The  long-term antibody decay rate can also be seen to be
strongly linear in log units. Table 2 gives the predicted and observed
median antibody titre and 5th to 95th percentile range at several
time points up to year 10.
Fig. 3. Prediction of the proportion of subjects seroprotected through time and 95%
credibility bands based on the piecewise linear model. Points represent the observed
seroprotection values. The red segment indicates the observation period for our data
and the blue segment the period of time over which the model is extrapolated. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web  version of the article.)
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Table 2
Observed and predicted decline of antibody titre and seroprotection rate.a
Observed Predicted
Median titres (5–95% range) Seroprotection (95% CI) Median titres (5–95% range) Seroprotection (95% CI)
28 days 230 (362,140) 97.9 (92.8, 99.7) 235 (69,829) 99.8 (98.9, 100)
6  months 149 (191,270) 96.8 (90.9, 99.3) 115 (23,562) 98.4 (96.9, 100)
1  year 102 (9890) 94.7 (87.1, 98.6) 106  (21,527) 97.5 (94.9, 98.9)
2  years 82 (5657) 90.1 (80.7, 95.9) 94 (19,466) 97.1 (94.9, 96.9)
3  years 102 (15,573) 96.5 (87.9, 99.6) 84 (16,412) 96.4 (93.9, 98.9)
4  years 76 (20,516) 98.2 (90.1, 99.9) 74 (14,365) 95.6 (92.9, 97.9)
5  years 70 (6304) 93.3 (82.1, 98.6) 66 (11,322) 94.7 (90.9, 97.9)
6  years 58 (10,284) 93.4 (88.8, 96.9)
7  years 52 (8252) 91.8 (85.8, 96.9)
8  years 47 (7222) 90.0 (81.8, 95.9)
9  years 42 (6197) 87.8 (77.7, 94.9)
3
r
p
s
i
T
r
y
s
t
5
C
(
s
3
s
h
b
a
t
2
r
9
F
l
o
e
t10  years 
a Predictions based on the piecewise linear model.
.3. Model predictions for seroprotection
Fig. 3 illustrates the predicted evolution of the seroprotection
ate. Unlike antibody titres, the predicted decline in the sero-
rotection rate is not linear. However, since by construction the
eroprotection rate derives from the distribution of antibody titres
n the population, the evolution of both indicators is closely linked.
he ﬁrst year following vaccination, the predicted seroprotection
ate is high but decreases quite rapidly (−2.3% between day 28 and
ear 1). The seroprotection rate declines at a slower rate during the
econd year than during the ﬁrst (−0.4%) but then accelerates from
his point onwards. This can be seen by a steeper curve after year
. In particular, at year 5 the predicted seroprotection is 94.7% (95%
I: 90.9–97.9) which is comparable to the observed value of 93.3%
95% CI: 82.1–98.6). At 10 years the predicted seroprotection level
till remains high at 85.5% (95% CI: 72.7–94.9).
.4. Model predictions for duration of protection
We calculated the percentiles for duration of protection in our
tudy population, or equivalently, the percentage of individuals
aving at least the given duration of protection by maintaining anti-
ody titres above the accepted threshold. The maximum, median
nd minimum duration of protection were calculated to be respec-
ively 38.1 years, 21.3 years and less than 28 days. Excluding the subjects who  were not seroprotected at 28 days (vaccine non
esponders), all subjects had at least 3.4 years of protection and
0% of subjects had at least 11.2 years of protection. Table 3 gives
ig. 4. Scatterplot of observed versus predicted Ab titres based on the piecewise
inear  model. Blue points correspond to observed and predicted value for the 535
bservations points. The red line is the identity line. (For interpretation of the ref-
rences to colour in this ﬁgure legend, the reader is referred to the web  version of
he article.)38 (5174) 85.5 (72.7, 94.9)
the percentiles for duration of protection in our study population
excluding the 2 non-responders.
3.5.  Model inference on change-point for antibody decay
The  change point for antibody decay refers to the time when the
initial period of rapid decline in titre ends and the second period of
slow decline begins. The average individual change point, as esti-
mated by the 2-period piecewise-linear model, was  0.267 years
(5th to 95th percentile range: 0.11–0.61). This means that antibody
titres after a single dose of JE-CV would continue to decline rapidly
from their peak value observed around day 28 until 3.2 months
after vaccination on average (5th to 95th percentile range: 1.4–7.3).
After this initial period of rapid antibody decline, titres continue to
decline but at a much slower rate (about 50 times slower).
4.  Discussion
Our analyses of the persistence of antibodies predict that the
seroprotection rate after a single dose of JE-CV in adults remains
high for at least 10 years. This conclusion is based on a median
antibody titre at 10 years of 38, which exceeds the seroprotective
threshold of 10 accepted by regulatory authorities as a surrogate
marker of protection [9]. Overall, we predicted that 85.5% of sub-
jects will maintain antibody titres above the threshold value 10
years after vaccination. The median duration of seroprotection
exceeded 20 years, and 90% of responding subjects had at least 11.2
years of protection.
We  also inferred from our analyses that there is an early, short
period of rapid antibody decline ending during the 4th month after
vaccination (3.2 months on average), after which a second period
of much slower antibody decay ensues for many years. These two
separate periods of antibody decay were supported by the DIC sta-
tistical criterion which strongly selected the piecewise linear model
over other models considered. This has important implications for
the interpretation of immunogenicity measurements made after
Table 3
Predicted duration of protection after a single dose of JE-CV, excluding 2 non
responders.a
Percentile Duration of protection (years)
Maximum 38.1
90th 31.9
75th 27.0
50th 21.4
25th 15.2
10th 11.2
Minimum 3.3
a Predictions based on the piecewise linear model.
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he 4th month post-vaccination. In particular, the change point
ould imply that immunogenicity measurements made during the
econd slower period of antibody decay, for example at 6 months,
re indicative of longer-term seroprotection levels.
Our estimation of the duration of this initial period of rapid
ecline should be interpreted with some caution as it is dependent
n the number of observation points during the ﬁrst year post-
accination. We  were able to rely in our analysis on measurements
ade at days 28, 56 and at 6 months but more observation points
etween 6 months and 1 year after vaccination would have helped
eﬁne this analysis.
Apart  from the number of available antibody measurements,
ur study had three main limitations. Firstly we used data col-
ected in study conducted in adults in an area where JE does not
irculate. Our estimates would therefore likely to be conservative
f applied to populations living in areas where the virus is endemic.
he study population for our analyses were mostly ﬂavivirus-
egative at baseline (10% positive to ﬂaviviruses and 5% positive
o JE and dengue speciﬁcally) with limited natural exposure. In set-
ings where exposure to JE is more common, natural boosting is
ikely to lead to higher antibody titres and longer-lasting seropro-
ection. Another source of potential bias is the loss to follow-up
y year 5 if the distribution of early antibody titres was differ-
nt among those still present at year 5 versus those who  were
ot. However, we compared antibody titres observed at 6 months
etween these two sub-groups and found no difference (p = 0.51;
ruskal–Wallis test of centrality). Another limitation of our study
s that the ﬁndings were restricted to adults. Our conclusions may
ot extend to a paediatric population; antibody persistence data in
hildren and toddlers would help conﬁrm our ﬁndings for younger
ge groups.
Our analyses were based on data from a study described in a
revious paper [11]. While the overall conclusions on the long-
erm seroprotection concord, some of our ﬁndings differ from
hose reported in this paper. This can in fact be explained by
ifferences in the methodological approach. They notably chose
he Kaplan–Meier method as their primary statistical analysis and
ound that 87% of 90 subjects who did not receive a second dose of
E-CV and who were seroprotected at 6 months were still protected
t 5 years. Unlike the Kaplan–Meier method, our analyses keeps
nder observation those subjects who miss one antibody test but
eturn for a test in a later year. Our estimate of protection at year
 was more optimistic at 93.5% amongst those seroprotected at 28
ays. This is also reﬂected in our model-based estimate of 94.7%
eroprotection at 5 years.
To our knowledge, ours is the ﬁrst application of statistical
odels to study antibody persistence against JE disease. The mod-
lling approach to study antibody persistence has been used for
ther vaccine-preventable diseases, including diphtheria [16,17],
epatitis A [18], hepatitis B [19], meningitis A [20], pertussis [21]
nd HPV [22] to address questions of duration of protection and
eed and timing of boosters. These previous efforts utilize either
n exponential-type or a linear modelling approach depending on
hether antibody titres were log-transformed or not. While all
pproaches sought to explain the population-level evolution of
ntibody titres, not all considered the individual-level of variability
ith mixed-effect models as we did. By considering different model
tructures (linear, piecewise linear, exponential-type) using mixed
ffects, we were able to study the sensitivity of our conclusions on
unctional assumptions while capturing individual-level effects.
Our  predictions required us to extrapolate data beyond the 5
ear period of observation, which implicitly assumes that the linear
ate of antibody decay (in log-units) must continue after 5 years.
ased on our model comparisons, the linear assumption is justi-
ed, and this is also supported by antibody persistence studies for
ther diseases [17,21]. By limiting our main conclusions to 10 years,
[ (2012) 2510– 2515
we  were cautious not to extrapolate too far into the future as the
uncertainty in predictions increases.
In conclusion, the analysis performed enabled us to charac-
terize the antibody decay after JE-CV vaccination as follows: a
short period of rapid decline no longer than 6 months followed
by a decay at a much slower rate. The results obtained also high-
lighted that one dose of JE-CV provided most adults living in a
non-endemic area with seroprotection for more than 10 years.
Considering the natural boosting that could occur in a population
exposed to circulating virus, our results are probably underesti-
mate the duration of seroprotection in endemic areas. Provided
that data become available, a useful extension of this work would
be the estimation of the persistence of JE-CV vaccine-induced
antibodies in a paediatric population living in areas where JE is
endemic.
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